<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153188">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02106390</url>
  </required_header>
  <id_info>
    <org_study_id>V72_56</org_study_id>
    <nct_id>NCT02106390</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants</brief_title>
  <official_title>A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Mexico: Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability
      of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at
      3, 5, 7 and 13 months of age, compared to either alone.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Between-group ratios of hSBA Geometric Mean Titers (GMTs)  for all serogroups B (all indicator strains), A, C, W-135 and Y.</measure>
    <time_frame>30 days after 4th vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate the immunological non-inferiority of rMenB+OMV NZ and MenACWY when concomitantly administered compared to either alone, at one month following the fourth vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hSBA GMT, percentage of subjects with hSBA ≥1:5 and percentage of subjects with hSBA ≥ 1:8 against serogroups B (all indicator strains), A, C, W-135 and Y</measure>
    <time_frame>30 days after 3th vaccination, pre-4th vaccination and 30 days after 4th vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the immune response of rMenB+OMV NZ and MenACWY when concomitantly administered compared to either alone at
one month after the fourth vaccination
one month  after the third vaccination
six months after the third vaccination
To asses the safety and tolerability of rMenB+OMV NZ and MenACWY when concomitantly administered compared to either alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Within subject Geometric Mean Ratios (GMRs) and percentage of subject with four-fold increase in hSBA titers, at one months after fourth vaccination versus pre-fourth vaccination</measure>
    <time_frame>30 days after 4th vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with solicited AE, unsolicited AE, medically attended AEs, AEs leading to withdrawn and SAEs</measure>
    <time_frame>participants will be followed for the duration of study, within an expected average of 11 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co-administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MenB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MenACWY</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV  and MenACWY</intervention_name>
    <description>rMenB+OMV  given concomitantly with MenACWY at 3,5,7 and 13  months of age</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV</intervention_name>
    <description>rMenB+OMV  given at 3,5,7 and 13 months of age</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY</intervention_name>
    <description>MenACWY given at 3,5,7 and 13 months of age</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 3-month old infants whose parents/legal guardians have given written informed
             consent

          -  Available for all the visits scheduled in the study.

          -  In good health as determined by medical history, physical examination and clinical
             judgment of the investigator.

        Exclusion Criteria:

          -  History of any previous immunization with a meningococcal vaccine or vaccine
             containing meningococcal antigen(s) (licensed or investigational) at the time of
             enrollment.

          -  Previous known or suspected disease caused by N. meningitidis.

          -  Household contact with and/or intimate exposure to an individual with laboratory
             confirmed N. meningitidis infection or colonization.

          -  Family members or household members of site research staff.

          -  History of severe allergic reaction after previous vaccinations, or hypersensitivity
             to any component of the vaccine.

          -  Known or suspected autoimmune disease or impairment/alteration of the immune system

          -  Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation since birth.

          -  History of any progressive or severe neurologic disorder, or seizure disorder or
             Guillan Barré syndrome (exception: one self-limited febrile seizure is acceptable).

          -  Receipt of any investigational or non-registered product (drug or vaccine) since
             birth (3 month prior) or are expected to receive during the study period.

          -  History or any illness/condition that, in the opinion of the investigator, might
             interfere with the results of the study or pose additional risk to the subjects due
             to participation in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>85 Days</minimum_age>
    <maximum_age>119 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 401</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>(C1425DEM)</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alejandro Capdevila</last_name>
      <phone>(5411) 4806-1350</phone>
      <email>vax_ar@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 402, Dr Norberto Giglio / Veronica Umido</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>(C1425EFD)</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Leonor Spagnuolo de Gentile</last_name>
      <phone>54 11 4964-9019</phone>
      <email>angelagentile@fibertel.com.ar; agentile@intramed.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 404, Fernando Aguirre / TBC</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1426EOT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo Ruttiman</last_name>
      <phone>54 9 1115 6120-4819</phone>
      <email>r.ruttimann@speedy.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 404, Noelia Barraza</name>
      <address>
        <city>Mendoza</city>
        <zip>(5519)</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Héctor José Abate</last_name>
      <phone>0261-4454775</phone>
      <email>hjabate@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis, vaccination, infant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
